ITC is anticipated to reveal moderate revenue growth, driven by cigarettes and agri businesses, while Sun Pharma is expected to showcase high single-digit bottom-line growth, fueled by strong domestic performance. Revenue growth for Sun Pharma is expected to be 9% year-on-year, while ITC’s revenue is expected to rise 2% year-on-year. Analysts anticipate $500 million in US sales for Sun Pharma.
Bandhan Bank Q4 business update: Advances rise to Rs 1.54 lakh crore, deposits up 10%
Bandhan Bank reported a 12.6% YoY rise in advances to Rs 1.54 lakh crore and 10% growth in total deposits for Q4 FY26. Retail deposits